MEDIA ALERT: AOP Webinar Spotlights Contrast Management for Myopia Control
CPD-Accredited Clinical Lecture to Connect Contrast Management Research with Practical Application for UK Eye Care Professionals
Eye care professionals are invited to explore the broadening evidence base for contrast management as an approach to slowing myopia progression in children during a CPD-accredited webinar. On 22 September at 7 pm UK time, the Association of Optometrists (AOP) will host “Understanding Contrast Management for Myopia Control,” in partnership with SightGlass Vision.
The one-hour lecture will feature James Wolffsohn, Professor of Optometry at Aston University and Chief Clinical Scientist for the International Myopia Institute, and David Webley, Senior Director, Clinical, Medical and Professional Affairs at SightGlass Vision.
UK eye care professionals interested in attending the webinar can register here.
The webinar will explore the role of contrast management in controlling myopia progression, examining the principles behind this approach and its relevance to clinical care. Prof. Wolffsohn will lead the discussion, providing eye care professionals with the scientific and clinical foundations of contrast management, with Webley sharing the results from a number of recent clinical studies.
While most myopia control spectacle lenses work through peripheral defocus, contrast management represents a unique approach to myopia management. DOT® spectacle lenses, powered by Diffusion Optics Technology®, are the first myopia management treatment specifically
designed to reduce retinal contrast signaling through the incorporation of light scattering elements.1* The latest clinical data supporting this approach include newly released 24-month data showing that children aged 6-10 saved more than 1D of progression on average after two years.2†‡
Practitioners attending the lecture live can earn one Continuing Professional Development (CPD) point. For more information on the 22 September webinar, visit the registration page.
###
About SightGlass Vision
SightGlass Vision™ develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on landmark discoveries surrounding myopia progression. DOT™ spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina. DOT™ lenses provide myopia control through contrast management and have proven results from Gold-standard clinical trials in North America and China. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.
* Not available for sale in all countries, including in the U.S
† Prescribed DOT lens wear time was 10 hours per day. LS mean progression difference of 1.01D between test and control groups.
‡ Study conducted among Chinese population (n = 172, 5 sites in China). Patient population aged 6–13 years.
Diffusion Optics Technology and DOT are trademarks of SightGlass Vision, Inc.© 2026 SightGlass Vision, Inc. All Rights Reserved.
Media Contact
Carson Daniels, Senior Counselor
McDougall Communications for SightGlass Vision
+1-315-427-6394 or [email protected]
1 Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023;107(11):1709–1715.
2 SGV data on file 2026. Control of myopia using contrast modulation spectacle lenses in a Chinese population (n = 172 (6-10 years: 117), 5 sites in China). Overall patient population aged 6–13 years. The clinical trial was designed to compare DOT lenses with conventional singlevision lenses to evaluate their continued safety and efficacy in Chinese children.